Skip to main navigation menu Skip to main content Skip to site footer

Mycobacterium abscessus complex lung infection

Infección pulmonar por Mycobacterium abscessus complex




Section
Presentación de casos

How to Cite
Mycobacterium abscessus complex lung infection.
rev. colomb. neumol. [Internet]. 2018 Nov. 13 [cited 2024 Dec. 22];30(1):47-51. Disponible en: https://doi.org/10.30789/rcneumologia.v30.n1.2018.301

Dimensions
PlumX
license

Ninguna publicación, nacional o extranjera, podrá reproducir ni traducir sus artículos ni sus resúmenes sin previa autorización escrita del editor; sin embargo  los usuarios pueden descargar la información contenida en ella, pero deben darle atribución o reconocimiento de propiedad intelectual, deben usarlo tal como está, sin derivación alguna.


Non-tuberculous mycobacteria (NTM) are ubiquitous. Factors of the host, defects of the immune system, structural alterations of the pulmonary parenchyma and environmental factors influence the development of disease. We present the case of a patient who meets the diagnostic criteria proposed for pulmonary infection secondary to a rapidly growing NTM type Mycobacterium abscessus complex which has a broad intrinsic resistance and requires combination antimicrobial therapy based on macrolides and long duration with low levels negativization rates of sputum cultures.

Article visits 611 | PDF visits 1406


Downloads

Download data is not yet available.
  1. Koh WJ, Stout JE, Yew WW. Advances in the management of pulmonary disease due to Mycobacterium abscessus complex. Int J Tuberc Lung Dis [Internet]. 2014;18(10):1141-8. Disponible en: http://dx.doi.org/10.5588/ijtld.14.0134.
  2. Johnson MM, Odell JA. Nontuberculous mycobacterial pulmonary infections. J Thorac Dis. 2014;6(3):210-20.
  3. Kwon YS. Diagnosis and Treatment of Nontuberculous Mycobacterial Lung Disease. Korean J Med. 2012;82(3):274.
  4. Medjahed H, Gaillard JL, Reyrat JM. Mycobacterium abscessus: a new player in the mycobacterial field. Trends Microbiol [Internet]. 2010;18(3):117-23. Disponible en: http://dx.doi.org/10.1016/j.tim.2009.12.007.
  5. Aksamit TR, Philley JV, Griffith DE. Nontuberculous mycobacterial (NTM) lung disease: The top ten essentials. Respir Med [Internet]. 2014;108(3):417-25. Disponible en: http://dx.doi.org/10.1016/j.rmed.2013.09.014.
  6. Lee MR, Sheng WH, Hung CC, Yu CJ, Lee LN, Hsueh PR. Mycobacterium abscessus Complex Infections in Humans. Emerg Infect Dis [Internet]. 2015;21(9)1638-46. Disponible en: http://wwwnc.cdc.gov/eid/article/21/9/14-1634_article.htm.
  7. Koh WJ, Yu CM, Suh GY, Chung MP, Kim H, Kwon OJ, et al. Pulmonary TB and NTM lung disease: comparison of characteristics in patients with AFB smear-positive sputum. Int J Tuberc Lung Dis. 2006;10(9):1001-7.
  8. Obregón-Henao A, Arnett KA, Henao-Tamayo M, Massoudi L, Creissen E, Andries K, et al. Susceptibility of Mycobacterium abscessus to antimycobacterial drugs in preclinical models. Antimicrob Agents Chemother. 2015;59(11):6904-12.
  9. Nessar R, Cambau E, Reyrat JM, Murray A, Gicquel B. Mycobacterium abscessus: A new antibiotic nightmare. J Antimicrob Chemother. 2012;67(4):810-8.
  10. Koh WJ, Jeong BH, Kim SY, Jeon K, Park KU, Jhun BW, et al. Mycobacterial Characteristics and Treatment Outcomes in Mycobacterium abscessus Lung Disease. Clin Infect Dis [Internet]. 2017;64(3):309-16. Disponible en: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw724.
  11. Aziz DB, Low JL, Wu ML, Gengenbacher M, Teo JWP, Dartois V, et al. Rifabutin Is active against Mycobacterium abscessus Complex. Antimicrob Agents Chemother. 2017;61(6).
  12. Mukherjee D, Wu ML, Teo JWP, Dick T. Vancomycin and Clarithromycin Show Synergy against Mycobacterium abscessus In Vitro. Antimicrob Agents Chemother. 2017;61(12).
  13. Park J, Cho J, Lee CH, Han SK, Yim JJ. Progression and Treatment Outcomes of Lung Disease Caused by Mycobacterium abscessus and Mycobacterium massiliense. Clin Infect Dis [Internet]. 2017;64(3):301-8. Disponible en: http://cid.oxfordjournals.org/lookup/doi/10.1093/cid/ciw723
  14. Pasipanodya JG, Ogbonna D, Ferro BE, Magombedze G, Srivastava S, Deshpande D, et al. Systematic review and meta-analyses of the effect of chemotherapy on pulmonary Mycobacterium abscessus outcomes and disease recurrence. Antimicrob Agents Chemother [Internet]. 2017;61(11):AAC.01206-17. Disponible en: http://aac.asm.org/lookup/doi/10.1128/AAC.01206-17
  15. Alvarez-Uria G. Lung disease caused by nontuberculous mycobacteria. Curr Opin Pulm Med. 2010;16(3):251-6.
  16. McShane PJ, Glassroth J. Pulmonary disease due to nontuberculous mycobacteria current state and new insights. Chest. 2015;148(6):1517-27.
  17. Benwill JL, Wallace RJ Jr. Mycobacterium abscessus: challenges in diagnosis and treatment. Curr Opin Infect Dis [Internet]. 2014;27(6):506-10. Disponible en: http://content.wkhealth.com/linkback/openurl?sid=WKPTLP:landingpage&an=00001432-201412000-00007.
  18. Brown-Elliott BA, Vasireddy S, Vasireddy R, Iakhiaeva E, Howard ST, Nash K, et al. Utility of sequencing the erm(41) gene in isolates of Mycobacterium abscessus subsp. abscessus with low and intermediate clarithromycin MICs. J Clin Microbiol. 2015;53(4):1211-5.
  19. Rubio M, March F, Garrigó M, Moreno C, Español M, Coll P. Inducible and acquired clarithromycin resistance in the mycobacterium abscessus complex. PLoS One. 2015;10(10):e0140166.
  20. Kehrmann J, Kurt N, Rueger K, Bange FC, Buer J. GenoType NTM-DR for Identifyng Mycobacterium abscessus Subspecies and Determining Molecular Resistance. J Clin Microbiol. 2016;54(6):1653-5.
  21. Harada T, Akiyama Y, Kurashima A, Nagai H, Tsuyuguchi K, Fujii T, et al. Clinical and microbiological differences between Mycobacterium abscessus and Mycobacterium massiliense lung diseases. J Clin Microbiol. 2012;50(11):3556-61.
Sistema OJS 3.4.0.7 - Metabiblioteca |